Hopp til hovedinnhold
Personer uten symptomer behøver ikke behandling, men ved alvorlig talassemi er det helt nødvendig med hyppige, regelmessige blodoverføringer.
Personer uten symptomer behøver ikke behandling, men ved alvorlig talassemi er det helt nødvendig med hyppige, regelmessige blodoverføringer.

Talassemier

Talassemi er en medfødt gruppe av sykdommer som forårsaker anemi (lav blodprosent). Det finnes en rekke ulike typer talassemi, og alvorlighetsgraden varierer.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/blod/anemier/talassemi/ 

Hva er talassemi?

Symptomer

Diagnostikk

Behandling

Prognose

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Talassemier. Referanselisten for dette dokumentet vises nedenfor.

  1. Sheth S. Beta-thalassaemia. BMJ Best Practice, last updated November 2017. bestpractice.bmj.com 
  2. Benz EJ, Angelucci E. Clinical manifestations and diagnosis of the thalassemias. UpToDate, last updated Jan 17, 2020. UpToDate 
  3. Advani P. Beta thalassemia. Medscape, last updated Nov 08, 2016. emedicine.medscape.com 
  4. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155‐167. doi:10.1016/S0140-6736(17)31822-6 DOI 
  5. Rund D, Rachmilewitz E. Beta-Thalassemia. N Engl J Med 2005; 353: 1135-46. PubMed 
  6. Lilleholt K, Hallberg MH, Hagve T-A. Hemoglobinopatier og fremmedartede navn. Tidsskr Nor Lægeforen 2005; 125: 1164-7. PubMed 
  7. Cao A, Galanello R. Effect of consanguinity on screening for thalassemia. N Engl J Med 2002; 347: 1200-2. New England Journal of Medicine 
  8. Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am 2013; 60:1383. PubMed 
  9. Muncie HL, Campbell JS. Alpha and beta thalassemia. Am Fam Physician 2009; 80: 339-44. American Family Physician 
  10. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of {beta}-thalassemia major in North America. Blood 2004; 104: 34-39. Blood 
  11. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res 2002; 58 (Suppl 1): 72-79.
  12. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24. Blood 
  13. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet 2002; 360: 516-20. PubMed 
  14. Raiola G, Galati MC, De Sanctis V, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 2003; 16 (Suppl 2): 259-266.
  15. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127: 127-139. PubMed 
  16. Bhardwaj A, Swe KMM, Sinha NK, Osunkwo I. Treatment for osteoporosis in people with ß-thalassaemia. Cochrane Database of Systematic Reviews 2016, Issue 3. Art. No.: CD010429. DOI: 10.1002/14651858.CD010429.pub2 DOI 
  17. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-73. PubMed 
  18. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43. Blood 
  19. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2. PubMed 
  20. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93. PubMed 
  21. Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201-3. Blood 
  22. Krishnamurti L, Abel S, Maiers M, Flesch S. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 2003; 31: 547-550. PubMed 
  23. La Nasa G, Giardini C, Argiolu F, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002; 99: 4350-6. Blood 
  24. Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137-43. Blood 
  25. Fang J, Huang S, Chen C, et al. Umbilical cord blood transplantation in Chinese children with beta-thalassemia. J Pediatr Hematol Oncol 2004; 26: 185-9. PubMed 
  26. Braude P, Pickering S, Flinter F, Ogilvie CM. Preimplantation genetic diagnosis. Nat Rev Genet 2002; 3: 941-53. Erratum, Nat Rev Genet 2003; 4: 157.
  27. Piyamongkol W, Bermudez MG, Harper JC, Wells D. Detailed investigation of factors influencing amplification efficiency and allele drop-out in single cell PCR: implications for preimplantation genetic diagnosis. Mol Hum Reprod 2003; 9: 411-420. PubMed 
  28. Van de Velde H, Georgiou I, De Rycke M, et al. Novel universal approach for preimplantation genetic diagnosis of beta-thalassaemia in combination with HLA matching of embryos. Hum Reprod 2004; 19: 700-8. PubMed 
  29. Di Naro E, Ghezzi F, Vitucci A, et al. Prenatal diagnosis of {beta}-thalassemia using fetal erythroblasts enriched from maternal blood by a novel gradient. Mol Hum Reprod 2000; 6: 571-4. PubMed 
  30. Ding C, Chiu RWK, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci U S A 2004; 101: 10762-7. PubMed 
  31. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051–2.